Use of immunomodulatory therapy in children with pyoin-flammatory diseases
The addition of licopid to the complex therapy of children with the local form of acute hematogenic osteomyelitis allowed their earlier (by an average of 6±0.5 days fewer) activation, body temperature normalization, reductions in ESR and leukocytosis, and blood count normalization. The use of licopid caused a treatment time reduction. The significant decrease in the blood levels of proinflammatory cytokines (tumor necrosis factor-α, interleukin-1β) and C-reactive protein suggested that the intensity of the inflammatory process became less. Furthermore, a rapider healing of postoperative wounds was noted in licopid-treated children with pyoinflammatory diseases of soft tissues, which reduced the duration of antibacterial therapy by an average of 5 days. Treatment with licopid decreased the frequency of septic complications by 2,7 times (from 50 to 18,75%) and mortality rates by 2,4 times (from 15 to 6,25%).